PRICE T ROWE ASSOCIATES INC /MD/ - BIOXCEL THERAPEUTICS INC ownership

BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 83 filers reported holding BIOXCEL THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of BIOXCEL THERAPEUTICS INC
ValueSharesWeighting
Q4 2022$356
-99.8%
16,576
+1.1%
0.00%
Q3 2022$194,000
-0.5%
16,397
+11.2%
0.00%
Q2 2022$195,000
-33.2%
14,747
+5.7%
0.00%
Q1 2022$292,000
+9.8%
13,953
+6.8%
0.00%
Q4 2021$266,000
-17.9%
13,063
+22.2%
0.00%
Q3 2021$324,000
+4.9%
10,690
+0.6%
0.00%
Q2 2021$309,000
-37.6%
10,629
-7.2%
0.00%
Q1 2021$495,000
-5.7%
11,459
+0.8%
0.00%
Q4 2020$525,00011,3710.00%
Other shareholders
BIOXCEL THERAPEUTICS INC shareholders Q4 2022
NameSharesValueWeighting ↓
APIS CAPITAL ADVISORS, LLC 40,000$836,0001.01%
ACT CAPITAL MANAGEMENT, LLC 20,000$418,0000.44%
Knoll Capital Management, LLC 20,000$418,0000.26%
Artemis Investment Management LLP 1,428,228$29,855,0000.24%
Rubric Capital Management LP 268,528$5,615,0000.20%
Virtus ETF Advisers LLC 7,713$161,0000.07%
BOOTHBAY FUND MANAGEMENT, LLC 107,700$2,252,0000.05%
PDT Partners, LLC 28,031$586,0000.05%
AllSquare Wealth Management LLC 3,162$66,0000.04%
Hennion & Walsh Asset Management, Inc. 35,221$736,0000.04%
View complete list of BIOXCEL THERAPEUTICS INC shareholders